Dyadic International, Inc. (DYAI) vs Estrella Immunopharma, Inc. (ESLA)
A side-by-side comparison of Dyadic International, Inc. and Estrella Immunopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DYAI
Dyadic International, Inc.
$0.45HealthcareDelayed quote: Oct 6, 2026, 1:49 PM EDT
ESLA
Estrella Immunopharma, Inc.
$0.42HealthcareDelayed quote: Oct 6, 2026, 1:49 PM EDT
Total return — DYAI vs ESLA
growth of $100 · dividends reinvested · last 5yDYAI -92.2% (-40.0%/yr)ESLA -95.5% (-46.2%/yr)DYAI compounded faster over this window
DYAI ESLA
DYAI vs ESLA: by the numbers
- •ESLA is the larger company ($18M vs $16M market cap).
- •Both run net losses; ESLA's is the smaller (0.00% vs -219.50% net margin).
Metrics side by side
Valuation
| Metric | DYAI | ESLA |
|---|---|---|
| P/S ratio | 4.72 | N/A |
Profitability
| Metric | DYAI | ESLA |
|---|---|---|
| Gross margin | -88.25% | 0.00% |
| Operating margin | -579.88% | 0.00% |
| Net margin | -219.50% | 0.00% |
| ROIC | -279.48% | N/A |
Growth (annualized)
| Metric | DYAI | ESLA |
|---|---|---|
| Revenue CAGR (5Y) | -5.11% | N/A |
| Total return CAGR (5Y) | -38.53% | -46.34% |
Frequently asked
- How have DYAI and ESLA total returns compared?
- Over the past 5 years, DYAI delivered -38.53% and ESLA delivered -46.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.